Evidence map›Paper›PMID 37287312›Full record

ArticleRNA biology2023

PlmCas12e (CasX2) cleavage of CCR5: impact of guide RNA spacer length and PAM sequence on cleavage activity.

David A Armstrong, Taylor R Hudson, Christine A Hodge, Thomas H Hampton, Alexandra L Howell, Matthew S Hayden

Open access · goldAbstract read
In one paragraph

Article in RNA biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Enhanced cleavage of genomicRNA biology · 2025
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

David A ArmstrongResearch Service, V.A. Medical Center, White River Junction, VT, USA.ORCID 0000-0003-1748-2520
Taylor R HudsonResearch Service, V.A. Medical Center, White River Junction, VT, USA.
Christine A HodgeDepartments of Dermatology, Dartmouth Health, Lebanon, NH, USA.
Thomas H HamptonDepartments of Microbiology/Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.ORCID 0000-0003-0543-402X
Alexandra L HowellResearch Service, V.A. Medical Center, White River Junction, VT, USA.ORCID 0000-0002-2362-2596
Matthew S HaydenDepartments of Dermatology, Dartmouth Health, Lebanon, NH, USA.ORCID 0000-0003-1670-6430
Dartmouth College · USWhite River Junction VA Medical Center · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 2018 to 2026
$13.9M
Developing novel CRISPR/CasX editors to generate a CCR5/null immune systemI01BX005248 · VA · WHITE RIVER JUNCTION VA MEDICAL CENTER · PI ALEXANDRA L HOWELL · 2021 to 2026
–
BLRD VA I01 BX005248NCI NIH HHS P30 CA023108NIDDK NIH HHS P30 DK117469
6 · The paper itself

Abstract

Gene editing using CRISPR/Cas (clustered regularly interspaced palindromic repeats/CRISPR-associated) is under development as a therapeutic tool for the modification of genes in eukaryotic cells. While much effort has focused on CRISPR/Cas9 systems from

Indexed as

CRISPR-Cas SystemsGene EditingHumansMutationNucleotidesReceptors, CCR5RNACCR5 protein, humanNucleotidesReceptors, CCR5RNACasX2CCR5Crispr/CasGuide RNAPAM requirements

Identifiers

PMID37287312
PMCPMC10251783
OpenAlexW4379769557

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.